As part of the neuroscience therapeutic area partnership, which is now expanded to cardiovascular and metabolic diseases, Jubilant will deliver a steady stream of preclinical outcomes to AstraZeneca.
AstraZeneca will have the worldwide development and commercialization rights,
Jubilant derives research funding and success-based development and commercialization milestones.